Primary Outcome Measures Pre-treatment Prognostic Algorithm Validation [ Time Frame: 4 years ] The primary objective is to utilize a novel prognostic algorithm to predict the outcome of MPM patients. This algorithm includes 4 different tests: molecular, radiological, and blood based. It will be performed on 240 prospectively-collected samples. A score of 0-4 will[…]
Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will increase a tissue bank collection (CRB).
Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues
The purpose of the Dielectrics Properties of Thoracic Malignancies Study (DPTMS) is to provide a wealth of knowledge for investigators involved in establishing a new and effective treatment for a variety of solid tumors using tumor treatment fields. It is intended to provide biospecimen (tumor/healthy) together with demographic data (age, sex, race, occupational history, and other epidemiologic information), and clinical data (stage, treatment, survival information, and annotated CT’s). Our specific aims are to test the following hypotheses: 1) Electric properties of thoracic tumors differ from electric properties of surrounding healthy tissue 2) Different tumor types will have different electric properties 3) Electric properties of individual tumors are heterogeneous 4) Electric properties of tumors are related to the structure and composition of the underlying tissue 5) Use of standard medical imaging data (CT) will permit mapping of electric properties.
Primary Outcome Measures Prevalence of germline BAP1 variants in the unselected general population of cancer patients [ Time Frame: 5 years ] Clinical phenotypes (this includes premalignant lesions, tumor type and age of onset) in at risk blood-line family members of the patients [ Time Frame: 5 years ] Secondary Outcome Measures Environmental risk factors modifying cancer risk[…]
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy (MESOIMMUNE)
Primary Outcome Measures Disease control [ Time Frame: 12 weeks ] Disease control rate at 12 weeks Secondary Outcome Measures Survival with anti-PD1/PDL1 immunotherapy [ Time Frame: 12 weeks ] Overall survival from treatment with anti-PD1/PDL1 immunotherapy Duration of treatment [ Time Frame: 12 weeks ] Duration of treatment with PD1/PDL1 immunotherapy Survival [ Time Frame: 12 weeks ] Overall survival from the start of the[…]
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Toripalimab, pemetrexed and carboplatin in the treatment of locally advanced malignant MPM in 15 newly diagnosed patients with locally advanced malignant MPM.
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations
Primary Outcome Measures Occurrence of Dose Limiting Toxicity [ Time Frame: over the first 21 days of dosing ] Incidence of Adverse and Serious Adverse Events Occurrence of General Toxicity [ Time Frame: through study completion, an average of 30 months ] Incidence of Adverse and Serious Adverse Events, Discontinuations due to Adverse Events and general safety Evaluations[…]
Primary Outcome Measures safety of PB103 [ Time Frame: one year ] assessment of adverse events Secondary Outcome Measures efficacy of PB103 [ Time Frame: one year ] assessment of Progression Free Survival, PFS Inclusion Criteria Recipient: Recipients (Subjects) are between 20-70 years of age. Related donor: 6/6 matched at HLA-A, -B and -DRb1 or haploidentical donor ≥[…]
This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an MSLN-targeted CAR-T cell treatment with an anti-PD1 component is being given to people.
A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
This is a phase I, multi-center, open-label, multi-dose, two-part PK and safety study to characterize the DDI potential of oral Tazemetostat.